摘要
目的：评价吡柔比星与吉西他滨膀胱内灌注预防膀胱癌术后复发的疗效。方法：将42例保留膀胱手术治疗的膀胱癌患者分为A、B组，A组24例，B组18例。分别使用吡柔比星与吉西他滨进行预防灌注，全部患者均术后即刻膀胱内灌注化疗，每周1次，共6次；以后每月1次直至1-2年，并做随访和疗效比较。结果：A、B两组生存率均为100％；A组复发率为25％（6/24），B组复发率为27.8％（5/18），两组患者2年生存率、复发率比较差异无显著性意义（ P〉0.05）。A组和B组用药后膀胱刺激症状发生率、尿道狭窄发生率、全身不良反应发生率比较差异无显著性意义（ P〉0.05）。结论：吡柔比星与吉西他滨均可降低膀胱癌术后复发的机率，两者疗效无明显差异。膀胱内灌注预防浅表性膀胱癌术后复发近期疗效满意，副作用较轻，耐受性良好。
Objective：To evaluate the effect of prevention of postoperative recurrence of bladder cancer with intra-vesical between pirarubicin and gemcitabine. Methods：All 42 patients treated with bladder preservation surgery with bladder cancer were divided into A,B group. A group 24 cases,B group 1 8 cases . Respectively prevention infusionwith pirarubicin and gemcitabine. All patients were started one week after intravesical chemotherapy once a week for a total of six times,once a month until after 1 -2 years,and follow-up. Results：In A,B groups survival rates were 100%,recurrence rate was 25% in group A,27. 8% in group B,2-year survival rate,the recurrence rate difference was not statistically significant. The difference of the incidence of bladder irritation,urethral stricture incidence and systemic adverse reaction rate was not statistically significant. Conclusion：Pirarubicin and gemcitabine can reduce the chances of recurrence of bladder cancer,there is no significant difference in efficacy. Intravesical prophylaxis of super-ficial bladder cancer recurrence recent results were satisfactory,with less serious side effects.
出处
《现代肿瘤医学》
CAS
2015年第17期2463-2466,共4页
Journal of Modern Oncology
